• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MSBBecoming a substantial holder23/12/10
MSBAppendix 3B23/12/10
MSBMesoblast Completes Acquisition of AngioblastPRICE SENSITIVE23/12/10
MSBMesoblast And Cephalon Enter Into Strategic AlliancePRICE SENSITIVE08/12/10
MSBTrading HaltPRICE SENSITIVE06/12/10
MSBFinal Director's Interest Notice01/12/10
MSBResults of Meeting29/11/10
MSBDirector Appointment/Resignation29/11/10
MSBChairman's Address and CEO Presentation to AGM29/11/10
MSBMesoblast Clear To Proceed With Angioblast AcquisitionPRICE SENSITIVE19/11/10
MSBNovel Heart Attack Treatment Results Presented to US ForumPRICE SENSITIVE16/11/10
MSBUS Govt Grants for Further Development of Stem Cell ProductsPRICE SENSITIVE08/11/10
MSBAppendix 4C - quarterlyPRICE SENSITIVE29/10/10
MSBAnnual Report to shareholders29/10/10
MSBNotice of Annual General Meeting/Proxy Form29/10/10
MSBPositive Results From Phase 2 Lumbar Fusion TrialPRICE SENSITIVE21/10/10
MSBAngioblast Stockholders Approve Acquisition By MesoblastPRICE SENSITIVE20/10/10
MSBMesoblast Targets Broader Cancer IndicationsPRICE SENSITIVE14/10/10
MSBAppendix 3B06/10/10
MSBResults of EGM22/09/10
MSBAcquisition of US Company Ratified by Mesoblast Shareholders22/09/10
MSBChairman and CEO Presentations to EGM22/09/10
MSBMesoblast Featured at International Scientific Conferences20/09/10
MSBAppendix 3B13/09/10
MSBResponse to an ASX Price QueryPRICE SENSITIVE10/09/10
MSBIndependent Expert's Report August 201027/08/10
MSBPreliminary Final ReportPRICE SENSITIVE26/08/10
MSBMesoblast Financial Year End Results26/08/10
MSBMesoblast - Notice of Extraordinary General Meeting23/08/10
MSBOn Track for Phase 3 BMT Trial After Positive FDA MeetingPRICE SENSITIVE16/08/10
MSBAppendix 4C - quarterlyPRICE SENSITIVE30/07/10
MSBTGA Approval To Commercially Manufacture Stem Cell ProductsPRICE SENSITIVE21/07/10
MSBPhase 3 Meeting Set With FDA On Bone Marrow Regeneration12/07/10
MSBPhase 3 Meeting Set With FDA On Bone Marrow RegenerationPRICE SENSITIVE12/07/10
MSBAppendix 3B06/07/10
MSBAppendix 3B16/06/10
MSBMesoblast Featured at Inaugural ASX Singapore Conference28/05/10
MSBCeasing to be a substantial holder19/05/10
MSBAppendix 3B19/05/10
MSBUSA FDA Clears Phase 2 Trial For Cervical Spinal FusionPRICE SENSITIVE19/05/10
MSBMesoblast To Acquire Angioblast Systems, 37M Capital RaisingPRICE SENSITIVE12/05/10
MSBReinstatement to Official QuotationPRICE SENSITIVE12/05/10
MSBSuspension from Official QuotationPRICE SENSITIVE05/05/10
MSBTrading HaltPRICE SENSITIVE03/05/10
MSBAppendix 4C and Clinical Trial UpdatePRICE SENSITIVE30/04/10
MSBAppendix 3B30/04/10
MSBAppendix 3B09/04/10
MSBMarket Exclusivity Strengthened by New USA Healthcare ActPRICE SENSITIVE06/04/10
MSBKey Bone Repair Patent Granted in the United StatesPRICE SENSITIVE03/03/10
MSBAppendix 3B02/03/10
MSBStrong Progress, Well-Funded, Broadening Product Pipeline25/02/10
MSBHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
MSBAppendix 4C - quarterlyPRICE SENSITIVE29/01/10
MSBResponse to an ASX Price QueryPRICE SENSITIVE11/01/10
MSBMesoblast - National Electronic Media CoveragePRICE SENSITIVE21/12/09
MSBAppendix 3B18/12/09
MSBCells Regenerate Pancreas and Reduce Diabetic Glucose LevelsPRICE SENSITIVE18/12/09
MSBResults of Meeting30/11/09
MSBExecutive Director's Presentation to AGM30/11/09
MSBChairman's Address to the AGM - A Year of Solid Progress30/11/09
MSBAppendix 3B25/11/09
MSBChange of Director's Interest Notice25/11/09
MSBSustained 6 Month Improvement in Heart Muscle FunctionPRICE SENSITIVE18/11/09
MSBSuccessful Bone Marrow Regeneration in Cancer PatientsPRICE SENSITIVE06/11/09
MSBNotice of Annual General Meeting/Proxy Form28/10/09
MSBAnnual Report to shareholders28/10/09
MSBInvestor Briefing - The CEO Transcript26/10/09
MSBAppendix 3B16/10/09
MSBAppendix 4C - quarterlyPRICE SENSITIVE12/10/09
MSBCeasing to be a substantial holder06/10/09
MSBAppendix 3B30/09/09
MSBUBS Investor Conference In U.S. Features Angioblast24/09/09
MSBChange in substantial holding22/09/09
MSBEnrolment Complete for 2nd Group of Heart Failure PatientsPRICE SENSITIVE22/09/09
MSBDisc Repair Results Featured at Key Orthopaedic Conference15/09/09
MSBSuccessful Repair/Regeneration Damaged Intervertebral DiscsPRICE SENSITIVE10/09/09
MSBInvestor Briefing - The CEO Transcript01/09/09
MSBPreliminary Final ReportPRICE SENSITIVE26/08/09
MSBUSA Associate Company Closes $10M Equity-Based FinancingPRICE SENSITIVE25/08/09
MSBAssociate Company Angioblast Systems Raises New CapitalPRICE SENSITIVE19/08/09
MSBTrading HaltPRICE SENSITIVE17/08/09
MSBFDA Clears Trial in Minimally Invasive Lumbar Spinal FusionPRICE SENSITIVE17/08/09
MSBUSA Trial to use Patented Cells with Heart Assist DevicesPRICE SENSITIVE05/08/09
MSBLetter to Shareholders30/07/09
MSBAppendix 4C - quarterlyPRICE SENSITIVE30/07/09
MSBMSB to Apply for Regulatory Approval of Bone Repair ProductsPRICE SENSITIVE23/07/09
MSBAppendix 3B30/06/09
MSBMesoblast Featured on ABC-TV's Catalyst Program26/06/09
MSBInvestor Presentation to Australian Institutional Investors25/06/09
MSBPatients in Bone Marrow Trial Show Earlier EngraftmentPRICE SENSITIVE24/06/09
MSBResults Show Significant Heart Function ImprovementPRICE SENSITIVE14/05/09
MSBMesoblast - Letter from the Chairman05/05/09
MSBAppendix 4C - quarterlyPRICE SENSITIVE01/05/09
MSBMSB Commences Clinical Program for Fusion of Cervical SpinePRICE SENSITIVE28/04/09
MSBBecoming a substantial holder08/04/09
MSBAppendix 3B07/04/09
MSBChange in substantial holding02/04/09
MSBSection 708A Notice02/04/09
MSBAppendix 3B02/04/09
MSBMesoblast Raises Capital for New Clinical ProgramsPRICE SENSITIVE30/03/09
MSBBecoming a substantial holder
23/12/10
MSBAppendix 3B
23/12/10
MSBMesoblast Completes Acquisition of Angioblast
23/12/10PRICE SENSITIVE
MSBMesoblast And Cephalon Enter Into Strategic Alliance
08/12/10PRICE SENSITIVE
MSBTrading Halt
06/12/10PRICE SENSITIVE
MSBFinal Director's Interest Notice
01/12/10
MSBResults of Meeting
29/11/10
MSBDirector Appointment/Resignation
29/11/10
MSBChairman's Address and CEO Presentation to AGM
29/11/10
MSBMesoblast Clear To Proceed With Angioblast Acquisition
19/11/10PRICE SENSITIVE
MSBNovel Heart Attack Treatment Results Presented to US Forum
16/11/10PRICE SENSITIVE
MSBUS Govt Grants for Further Development of Stem Cell Products
08/11/10PRICE SENSITIVE
MSBAppendix 4C - quarterly
29/10/10PRICE SENSITIVE
MSBAnnual Report to shareholders
29/10/10
MSBNotice of Annual General Meeting/Proxy Form
29/10/10
MSBPositive Results From Phase 2 Lumbar Fusion Trial
21/10/10PRICE SENSITIVE
MSBAngioblast Stockholders Approve Acquisition By Mesoblast
20/10/10PRICE SENSITIVE
MSBMesoblast Targets Broader Cancer Indications
14/10/10PRICE SENSITIVE
MSBAppendix 3B
06/10/10
MSBResults of EGM
22/09/10
MSBAcquisition of US Company Ratified by Mesoblast Shareholders
22/09/10
MSBChairman and CEO Presentations to EGM
22/09/10
MSBMesoblast Featured at International Scientific Conferences
20/09/10
MSBAppendix 3B
13/09/10
MSBResponse to an ASX Price Query
10/09/10PRICE SENSITIVE
MSBIndependent Expert's Report August 2010
27/08/10
MSBPreliminary Final Report
26/08/10PRICE SENSITIVE
MSBMesoblast Financial Year End Results
26/08/10
MSBMesoblast - Notice of Extraordinary General Meeting
23/08/10
MSBOn Track for Phase 3 BMT Trial After Positive FDA Meeting
16/08/10PRICE SENSITIVE
MSBAppendix 4C - quarterly
30/07/10PRICE SENSITIVE
MSBTGA Approval To Commercially Manufacture Stem Cell Products
21/07/10PRICE SENSITIVE
MSBPhase 3 Meeting Set With FDA On Bone Marrow Regeneration
12/07/10
MSBPhase 3 Meeting Set With FDA On Bone Marrow Regeneration
12/07/10PRICE SENSITIVE
MSBAppendix 3B
06/07/10
MSBAppendix 3B
16/06/10
MSBMesoblast Featured at Inaugural ASX Singapore Conference
28/05/10
MSBCeasing to be a substantial holder
19/05/10
MSBAppendix 3B
19/05/10
MSBUSA FDA Clears Phase 2 Trial For Cervical Spinal Fusion
19/05/10PRICE SENSITIVE
MSBMesoblast To Acquire Angioblast Systems, 37M Capital Raising
12/05/10PRICE SENSITIVE
MSBReinstatement to Official Quotation
12/05/10PRICE SENSITIVE
MSBSuspension from Official Quotation
05/05/10PRICE SENSITIVE
MSBTrading Halt
03/05/10PRICE SENSITIVE
MSBAppendix 4C and Clinical Trial Update
30/04/10PRICE SENSITIVE
MSBAppendix 3B
30/04/10
MSBAppendix 3B
09/04/10
MSBMarket Exclusivity Strengthened by New USA Healthcare Act
06/04/10PRICE SENSITIVE
MSBKey Bone Repair Patent Granted in the United States
03/03/10PRICE SENSITIVE
MSBAppendix 3B
02/03/10
MSBStrong Progress, Well-Funded, Broadening Product Pipeline
25/02/10
MSBHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
MSBAppendix 4C - quarterly
29/01/10PRICE SENSITIVE
MSBResponse to an ASX Price Query
11/01/10PRICE SENSITIVE
MSBMesoblast - National Electronic Media Coverage
21/12/09PRICE SENSITIVE
MSBAppendix 3B
18/12/09
MSBCells Regenerate Pancreas and Reduce Diabetic Glucose Levels
18/12/09PRICE SENSITIVE
MSBResults of Meeting
30/11/09
MSBExecutive Director's Presentation to AGM
30/11/09
MSBChairman's Address to the AGM - A Year of Solid Progress
30/11/09
MSBAppendix 3B
25/11/09
MSBChange of Director's Interest Notice
25/11/09
MSBSustained 6 Month Improvement in Heart Muscle Function
18/11/09PRICE SENSITIVE
MSBSuccessful Bone Marrow Regeneration in Cancer Patients
06/11/09PRICE SENSITIVE
MSBNotice of Annual General Meeting/Proxy Form
28/10/09
MSBAnnual Report to shareholders
28/10/09
MSBInvestor Briefing - The CEO Transcript
26/10/09
MSBAppendix 3B
16/10/09
MSBAppendix 4C - quarterly
12/10/09PRICE SENSITIVE
MSBCeasing to be a substantial holder
06/10/09
MSBAppendix 3B
30/09/09
MSBUBS Investor Conference In U.S. Features Angioblast
24/09/09
MSBChange in substantial holding
22/09/09
MSBEnrolment Complete for 2nd Group of Heart Failure Patients
22/09/09PRICE SENSITIVE
MSBDisc Repair Results Featured at Key Orthopaedic Conference
15/09/09
MSBSuccessful Repair/Regeneration Damaged Intervertebral Discs
10/09/09PRICE SENSITIVE
MSBInvestor Briefing - The CEO Transcript
01/09/09
MSBPreliminary Final Report
26/08/09PRICE SENSITIVE
MSBUSA Associate Company Closes $10M Equity-Based Financing
25/08/09PRICE SENSITIVE
MSBAssociate Company Angioblast Systems Raises New Capital
19/08/09PRICE SENSITIVE
MSBTrading Halt
17/08/09PRICE SENSITIVE
MSBFDA Clears Trial in Minimally Invasive Lumbar Spinal Fusion
17/08/09PRICE SENSITIVE
MSBUSA Trial to use Patented Cells with Heart Assist Devices
05/08/09PRICE SENSITIVE
MSBLetter to Shareholders
30/07/09
MSBAppendix 4C - quarterly
30/07/09PRICE SENSITIVE
MSBMSB to Apply for Regulatory Approval of Bone Repair Products
23/07/09PRICE SENSITIVE
MSBAppendix 3B
30/06/09
MSBMesoblast Featured on ABC-TV's Catalyst Program
26/06/09
MSBInvestor Presentation to Australian Institutional Investors
25/06/09
MSBPatients in Bone Marrow Trial Show Earlier Engraftment
24/06/09PRICE SENSITIVE
MSBResults Show Significant Heart Function Improvement
14/05/09PRICE SENSITIVE
MSBMesoblast - Letter from the Chairman
05/05/09
MSBAppendix 4C - quarterly
01/05/09PRICE SENSITIVE
MSBMSB Commences Clinical Program for Fusion of Cervical Spine
28/04/09PRICE SENSITIVE
MSBBecoming a substantial holder
08/04/09
MSBAppendix 3B
07/04/09
MSBChange in substantial holding
02/04/09
MSBSection 708A Notice
02/04/09
MSBAppendix 3B
02/04/09
MSBMesoblast Raises Capital for New Clinical Programs
30/03/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.